Articles tagged with Drug Resistance
Researchers at Mass General Hospital identified a gene target, TANK-binding kinase 1 (TBK1), that enhances the effectiveness of cancer immunotherapy. Silencing TBK1 sensitizes tumor cells to immune attack, overcoming resistance to treatment.
Scientists have found a way to break down the resistance of mice with neuroendocrine pancreatic cancer to checkpoint blockade immunotherapy. A new drug combination, PD1-IL2v and anti-PD-L1, enhances anti-tumor immunity by stimulating specific T cells and reprogramming macrophages, leading to increased survival rates in tumor-bearing mice.
Researchers at Lund University discovered an antibody with potential to protect against Strep A infection and a rare form of binding that leads to effective immune response. The finding could explain why many Group A strep vaccines have failed.
MIT researchers have identified molecules found in mucus that can block cholera infection by interfering with the genes that cause the microbe to switch into a harmful state. The protective molecules, known as glycans, prevent Vibrio cholerae from producing the toxin that usually leads to severe diarrhea.
Scientists at the University of York have identified an enzyme that makes Leishmania infantum parasite resistant to miltefosine, a medication used to treat visceral leishmaniasis in Brazil. The discovery opens up potential for developing a blood test to predict patient outcome and tailor treatment to individual patients.
A study by North Carolina State University found that two common veterinary drugs, Fluralaner and Ivermectin, are effective in killing bed bugs on poultry farms. Fluralaner was highly effective against bed bugs with resistance to common insecticides.
Neuroblastoma tumour cells adapt to mimic embryonic cells, making them resistant to chemotherapy. This understanding can lead to targeted treatments that better reach the entire tumour and avoid resistance development.
Researchers at CNIO have identified epigenetic changes, specifically DNA methylation, as a key mechanism behind resistance to proteasome inhibitor drugs in multiple myeloma. This finding suggests that methylation levels in the PSMD5 gene can predict treatment response and potentially reverse resistance.
A study by CeMM researchers and the University of Dundee identifies mutations in E3 ligases that mediate resistances in cell cultures, but also finds that these mutations can be targeted by chemically modified degraders. This understanding has clinical relevance and enables further improvement of cancer therapy drugs.
A study reveals that interleukin 34 (IL-34) modulates the balance between two myeloid-derived suppressor cell populations, leading to immunosuppression and chemoresistance in triple-negative breast cancer. Neutralizing IL-34 with a drug reduces tumor growth and susceptibility to chemotherapy.
Researchers at UNIGE have discovered a way to overcome resistance to chemotherapy in colorectal cancer, using an optimized combination of tyrosine kinase inhibitors. This breakthrough opens up new avenues for developing targeted therapies that can effectively treat patients with low five-year survival rates.
Researchers found that sapanisertib can kill the malaria parasite at several stages during its life cycle, including in the liver and red blood cells. The study's findings offer new hope against a disease that kills over half a million people annually.
A new anti-virus has been discovered in a medical lecture. The lectin, known as H84T-BanLec, is highly effective against many different types of coronaviruses, including those causing COVID-19 and MERS-CoV. Its unique mechanism makes it difficult for viruses to develop resistance, making it a potential 'pan-coronavirus' antiviral drug ...
Researchers suggest new criteria for diagnosing sarcopenia, a syndrome characterized by loss of muscle mass and force, with lower cutoff points leading to improved prediction of mortality risk. The study found that raising handgrip strength thresholds can detect the onset of sarcopenia earlier and more accurately.
Researchers have successfully blocked the adhesion mechanism of Bartonella henselae bacteria, preventing cell infection. The discovery offers a promising new approach to combat highly resistant infectious agents like Acinetobacter baumannii.
A team of researchers at Baylor College of Medicine has investigated how breast cancer cells lose their ER expression, revealing a mechanism that explains the process and offers possibilities to overcome it. The study found that over-expressing 14-3-3τ in cancer cells leads to ER loss, with other molecular players such as AKT and GATA3...
A study reveals that BA.2.75.2, a new Omicron sublineage, largely evades neutralizing antibodies and is resistant to several monoclonal antibody treatments, posing an increased risk of SARS-CoV-2 infections this winter.
A new study identified a remdesivir-resistant version of COVID-19 in two kidney transplant patients treated with immunosuppressive drugs. The virus developed the V7921 gene mutation, which allows it to resist antiviral therapy, highlighting the need for continued monitoring and potential development of additional treatments.
Researchers replicate aggressive lymphoma to identify gene responsible for drug resistance, offering new targets and causes of resistance. The CRISPR activation technology enables the replication of complex diseases on an unmatched level.
Mayo Clinic researchers identified critical genomic changes associated with abiraterone acetate/prednisone resistance in advanced prostate cancer. An 11-gene drug panel predicted a worse prognosis for a subset of patients, and whole-exome sequencing data revealed mechanisms of acquired resistance.
Researchers found that ruxolitinib, a clinically approved drug, suppresses ICB-resistant melanomas by reprogramming TILs and relying on host TNF signaling. This discovery offers a potential target for bypassing therapeutic resistance in advanced melanoma patients.
Researchers have engineered an enzyme that can degrade the capsule of antibiotic-resistant B. anthracis bacteria, making it susceptible to the immune system. The new treatment, which combines the enzyme with a mouse antibody, shows promise in treating anthrax infections without antibiotics.
A study found that activation of the epidermal growth factor receptor (EGFR)-mediated signaling pathway is involved in lenvatinib resistance in thyroid cancer cells. Inhibition of EGFR by lapatinib therapy in combination with lenvatinib enhanced growth inhibitory effect and inhibited tumor growth more remarkably than monotherapy.
Researchers developed a novel, single-dose, intranasal treatment that reduces symptoms and viral shedding of multiple SARS-CoV-2 variants. The therapeutic interfering particle (TIP) treatment effectively blocks COVID-19 transmission in animal models.
A recent study finds that fungal infections during the pandemic are a significant public health problem with limited treatment options. The interaction between pathogen and host may be different in people with compromised immunity, leading to increased mortality rates among severe COVID-19 patients.
Researchers discovered that combining a new target with an old chemotherapy drug can reduce resistance and potentially improve treatment outcomes for small cell lung cancer. The study used mouse models to show that inhibiting a protein called SMYD3, along with cyclophosphamide, stopped tumors in their tracks.
A new study reveals that partner-drug resistance facilitates artemisinin resistance in malaria parasites. The research collaboration found a 10-fold increase in partner-drug resistant genotypes led to earlier artemisinin resistance establishment among these parasites, resulting in significant treatment failures globally.
Scientists at Baylor College of Medicine and the Broad Institute have identified biological markers associated with chemotherapy resistance in triple negative breast cancer. The study found that deletion on chromosome 19, specifically the LIG1 gene, is linked to resistance to treatment and poor clinical outcomes.
Researchers found that a gene called PTCHD1 plays a crucial role in opioid tolerance by altering cholesterol content in cell membranes. This discovery may lead to the development of new pain medications with lower overdose risk.
Researchers developed a new anti-cancer drug LP-182 that simultaneously targets two molecular signaling pathways responsible for cancer growth. The drug is absorbed through the gut's lymphatic system, maintaining optimal therapeutic levels over time.
Researchers at Moffitt Cancer Center have discovered that cancer-associated fibroblasts can both promote and inhibit drug sensitivity in non-small cell lung cancer cells, depending on the type of tumor cell and drug used. The study suggests that targeting specific signaling pathways, such as the insulin-like growth factor (IGF) pathway...
Researchers developed a statistical mapping tool to predict genetic markers of resistance to Plasmodium falciparum, the parasite that causes malaria. The model uses data from the WorldWide Antimalarial Resistance Network and fills in gaps by making continuous predictions in space and time.
A new AI algorithm has been developed to detect subtle brain abnormalities causing epileptic seizures. The Multicentre Epilepsy Lesion Detection project used over 1,000 patient MRI scans to train the algorithm, which was able to detect focal cortical dysplasia (FCD) in 67% of cases. This could lead to more patients being considered for...
A recent study from the University of Geneva suggests that ketamine's therapeutic use may be safe due to its limited impact on dopamine levels and neuronal communication. The research found that ketamine triggers a short increase in dopamine, but also inhibits a specific receptor that prevents addiction progression.
A study of over 500 patients with multiple myeloma reveals a high prevalence of genetic alterations in oncogenic pathways, leading to treatment resistance. The research found a specific link between RASopathies and mutations in these pathways, offering new insights into the development of resistance mechanisms.
A covalent DNA aptamer has been developed to overcome limitations of traditional aptamers in drug use. The semi-permanent inhibition by the aptamer may lead to unexpected side effects or a too-strong medicinal effect.
Researchers have found that high levels of iron can generate toxic free radicals, which damage lipids and ultimately lead to cell death. The team is exploring the use of compounds like JKE-1674 to induce ferroptosis in prostate cancer cells, making them more vulnerable to treatment.
The study reveals how the EGF receptor changes its shape when binding to its target, triggering cell growth and proliferation. The findings could lead to the design of new cancer drugs that evade resistance, says MIT chemist Gabriela Schlau-Cohen.
Researchers have found that tumor cells co-exist with normal tissue in a complex, heterogeneous mixture, leading to unexpected effects on therapeutic resistance. The study suggests that understanding these ecological interactions could lead to novel treatment strategies and improved patient outcomes.
A Moffitt study shows that adaptive therapy using abiraterone improves patient outcomes and reduces care costs. The approach delays treatment withdrawal to prevent resistant cells from proliferating, leading to longer median time to progression and overall survival.
Researchers at the Netherlands Cancer Institute discovered that prostate cancer cells hijack the circadian rhythm to become resistant to hormone therapy. The study found that proteins regulating the circadian clock play a crucial role in tumor cell survival, offering a potential target for new treatment strategies.
A UC San Diego study suggests COVID-19 rebound symptoms after taking Paxlovid are likely caused by insufficient drug exposure, not resistance or impaired immunity. The study found the virus remained sensitive to the drug and no relevant mutations were detected.
Researchers at Tokyo Medical and Dental University have developed a liquid biopsy that can determine if an esophageal cancer patient will respond to certain treatments. The biopsy uses a panel of mRNAs and microRNAs to predict patient outcomes, with improved accuracy when combined with tumor size data.
A new study published in Science Translational Medicine reveals that consecutive molecular modifications of the androgen receptor can contribute to drug resistance in prostate cancer. Researchers identified a potential treatment approach using an ACK1 inhibitor to block this resistance.
Researchers have reported encouraging early-stage data for the Phase 1 clinical trial of INB-200, a gamma-delta T cell-based immunotherapy. All patients enrolled in the trial have exceeded their expected progression-free survival, with two patients exceeding overall survival as well. The treatment shows promising activity against gliob...
A recent study published in Frontiers in Cardiovascular Medicine found that transcranial direct current stimulation (tDCS) can lower blood pressure in patients with resistant hypertension. After a single session or ten sessions, the treatment reduced peripheral and central blood pressure in some patients by up to 15 mmHg.
Deep nerve stimulation using custom-wired electrodes and wireless implantable systems significantly lowers systolic blood pressure by up to 16% in two hours. The technology targets hypertension, a leading cause of death globally, affecting over 1 billion people.
Researchers have identified glycans in mucus that can prevent Candida albicans from causing infection. These molecules can be used to develop new antifungal medicines or make disease-causing fungus more susceptible to existing drugs.
A Phase 3 clinical trial is investigating the effectiveness of a combination of two immunotherapy drugs, nemvaluekin alfa and pembrolizumab, compared to standard chemotherapy for patients with platinum-resistant ovarian cancer. The trial aims to provide a novel treatment option with better efficacy and safety profiles.
Researchers have identified new biomarkers to detect non-small cell lung cancer in its early stages through a blood test, offering improved survival chances. The approach can also identify potential drug resistance, allowing clinicians to choose alternative treatment options.
Researchers at Rice University have developed molecular machines that can kill bacteria using visible light, targeting gram-negative and gram-positive bacteria. The breakthrough study uses rotors spinning at millions of times per second to break up biofilms and persister cells, making these infections more treatable.
Researchers from UToledo found that a dominant gut bacteria species, Coprococcus comes, can break down quinapril and ramipril, reducing their efficacy. This study provides insights into the impact of gut bacteria on blood pressure medication, potentially leading to new ways to overcome treatment-resistant hypertension.
Researchers developed an algorithm to quickly identify two cancer drugs that work well together, reducing testing time from three years to eight weeks. The new method uses gene expression data to prioritize potential combinations and has been confirmed in lab tests.
Researchers at Gladstone Institutes have developed a novel class of therapeutics called feedback disruptors that target viral proteins' negative feedback loops. These drugs break the genetic feedback circuits, causing infected cells to self-destruct and stopping infection in its tracks.
Researchers at H. Lee Moffitt Cancer Center & Research Institute have identified key factors impacting the effectiveness of adaptive therapy in cancer treatment. The study found that spatial organization and competition between drug-resistant cells play a crucial role in determining the success of adaptive therapy.
Researchers have discovered a way to suppress a specific protein that promotes resistance to drugs commonly used to treat AML patients. This breakthrough has the potential to revolutionize treatment and prolong survival for those affected by the disease.
Researchers developed a deep learning-based model to predict drug-drug interactions using gene expression data. The DeSIDE-DDI model can identify potentially dangerous pairs and act as a drug safety monitoring system, helping establish the correct usage of drugs in the development phase.
Researchers at Brookhaven National Laboratory discovered an aberrant protein that mimics the action of aminoglycoside antibiotics, which could help scientists understand how those drugs kill bacterial cells. The newly identified protein could lead to the development of new inhibitors to target bacterial growth.
The University at Buffalo is developing new treatments for ovarian cancer by targeting the apelin receptor. Ovarian cancer cells rely on lipids for energy and survival, making this a promising therapeutic target.
Researchers found six cases of drug-resistant Aspergillus fumigatus infection linked to environmental spores. The fungus, common in soil and compost, has become resistant to antifungal drugs due to agricultural use, posing a growing threat to lung health.